Goiter Frequency Is More Strongly Associated with Gastric Adenocarcinoma than Urine Iodine Level

PURPOSE: We designed our study to evaluate the hypothesis that gastric cancer is correlated with iodine deficiency or thyroid dysfunction. MATERIALS AND METHODS: We investigated the total body iodine reserve, thyroid function status and autoimmune disorder in 40 recently diagnosed gastric adenocarcinoma cases versus 80 healthy controls. The participants came from a region with high gastric cancer rate but sufficient iodine supply due to salt iodination. The investigation included urine iodine level, thyroid gland clinical and ultrasonographic examination, and thyroid function tests. RESULTS: Goiter was detected more frequently in the case group (P=0.001); such a finding, however, was not true for lower than normal urine iodine levels. The free T3 mean level was significantly lower in the case group compared to the control group (P=0.005). CONCLUSIONS: The higher prevalence of goiter rather than low levels of urinary iodine in gastric adenocarcinoma cases suggests that goiter, perhaps due to protracted but currently adjusted iodine deficiency, is more likely to be associated with gastric adenocarcinoma compared to the existing iodine deficiency itself.

[Conventional chemoradiation with cisplatin versus hemoradiation with cisplatin plus gemcitabine in uterine cervical cancer]

Due to high mortality and morbidity of the cervical cancer we decided to compare benefits and advers effects of Gemcitabine plus conventional chemoradiation with conventional chemoradiation with cisplatin alone in Imam Hossein hospital, in Tehran, Iran. This double blind clinical trial, was carried out on 34 patients with documented cervical carcinoma during 2006-07 the patients divided into two sub groups: [A]Conventional concurrent chemoradiation with cisplatin[N=18] versus[B] concurrent chemoradiation with cisplatin plus gemicitabine [N=16]. The patients with clinical stage of IB2-IVA and normal cell blood count with normal renal and liver function tests included in the study. Irradiation was delivered to all patients through external and internal beams with same dose and schedule. The patients followed for 3 months at least. Clinical response rate and adverse events included Neutropenin, Thrombocytopenia, anemia, diarrhea, nausea, and vomiting compared in two groups with fisher exact test, and t-test Despite increasing of complete response rate with adding gemcitabine to conventional treatment[81.2% vs. 66.7%], the difference in two groups was not statistically significant. This study indicated that the addition of gemicatabine to conventional chemoradiation with cisplatinrevealed no significant benefits. All adverse events in combination chemotherapy group were greater than conventional treatment